Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap. Read more
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection. Read more
During the Closing Ceremony, five early-career, trainee, or resident investigators were honored for presenting at LALCA 2023. Read more
Patient Advocates Committee Chair Jill Feldman said ensuring the patient voice is present in research helps to improve the work being done to reduce the burden of lung cancer worldwide. Read more
Dr. Carolyn Dresler Joins Action on Smoking and Health (ASH) Board of Trustees; Novel Liquid Biopsy Assay for Lung Carcinoma Detection Receives FDA Breakthrough Device Designation. Read more
As LALCA 2023 gets under way in Montevideo, Uruguay, hear from chairs Drs. Luis Ubillos, Mario Varangot, Clarissa Mathias, and Carlos Barrios about the science that will be discussed. Read more
Despite Evidence of Benefit, Developing Countries Often Lack Routine Lung Cancer Screening Practices
Expert panel to discuss challenges and opportunities for increasing LDCT screening in Latin America during LALCA 2023. Read more
Highlighted studies explore the association of TP53 mutations with inferior prognosis in NSCLC patients of African ancestry, the possibilities for next-generation sequencing to guide therapy, and the use of a 12-gene expression panel to predict treatment benefit. Read more
China approves mobocertinib for patients with EGFR Exon20 insertion+ NSCLC; Deadline approaching for IASLC 2023 Lectureship and Distinguished Service Award Nominations. Read more
Dr. Emily Stone will succeed JTO Clinical and Research Reports founding editor Dr. Alex A. Adjei, who will remain editor-in-chief of the Journal of Thoracic Oncology. Read more